Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IQWIG

Cell and gene therapies: on course for commercial success?

Funding and reimbursement of cell and gene therapies pose a major challenge as payers consider how to evaluate a commercial proposition that is completely divergent from the traditional pharmaceutical model....

- PMLiVE

NICE blocks second Alexion rare disease drug in a week

Says high cost and “considerable uncertainties” over long-term benefits prohibit routine NHS use

- PMLiVE

Winning the war against cancer

Dr Josep Figueras on survival, access to treatments and the need for good data in oncology

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s Ibrance over high cost

Draft guidance on breast cancer therapy calls for more evidence of its benefits

- PMLiVE

NICE to bring HTA processes to mobile health apps

But its new evidence briefings will stop short of issuing guidance on their use

- PMLiVE

NICE U-turn on Imbruvica sees the leukaemia therapy backed for NHS use

Institute reverses its initial verdict on Janssen's oncology treatment

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

- PMLiVE

A rare talent

Shire’s Sebastian Stachowiak on dealing with change and working for a fit-for-purpose orphan drug environment

- PMLiVE

Sobi looks to real-world trial to push Elocta take-up

Aims to show haemophilia A treatment’s benefit to reimbursement authorities

UK flag

May says UK’s science base is a “negotiating priority” for Brexit

Stokes confidence in UK pharma as science and innovation featured among 12 key priorities

Market access in Europe: balancing access and affordability

European governments continue to pursue national agendas for market access, while also exploring opportunities to work together to achieve lower prices for new drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links